NovoCure Limited (NASDAQ:NVCR) Given Consensus Recommendation of “Moderate Buy” by Analysts
NovoCure Limited (NASDAQ:NVCR – Get Free Report) has been given a consensus recommendation of “Moderate Buy” by the six analysts that are presently covering the stock, Marketbeat Ratings reports. Two research analysts have rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average 12-month price target […]
NovoCure Limited (NASDAQ:NVCR – Get Free Report) has been given a consensus recommendation of “Moderate Buy” by the six analysts that are presently covering the stock, Marketbeat Ratings reports. Two research analysts have rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average 12-month price target […]
